In today’s competitive health care market, pharmaceutical and medical manufacturers rely on partners with a deep understanding of not only the industry’s challenges and requirements, but also its opportunities and promise for growth and development. Thus, Datwyler’s new health care offering, which was exclusively presented to select media and trade journalists at INTERPHEX 2017 in New York City, will leverage both the company‘s superior expertise and its strong sense for future trends in order to advance global health care. More than ever, Datwyler will act as a vital link between medical and pharmaceutical manufacturers and their patients to create a safer and more innovative medical environment for tomorrow. The roll-out of the new health care offering, effective immediately, will further drive Datwyler’s role as a global thought leader, bringing the most advanced and high-in-demand products to the worldwide market.
Shaping the future of the global health care industry
With the introduction of the new health care offering, Datwyler is doing more than taking part in the industry as a key market player: the company is establishing itself as a true and reliable partner to its customers, enabling them to maintain a competitive edge in the digital age. As for their new offering strategy, Datwyler identified three key opportunities: Patient Safety – Future Health – Global Leadership.
Patient safety: Excellent hygienic standards and a zero-defect policy are essential parts in moving towards the establishment of a patient safety standard that goes beyond fulfilling regulatory requirements. Particle level management in the area of drug packaging is one of the main concerns of pharmaceutical and medical companies. Datwyler has pushed the limits and is able to guarantee its customers the lowest available particle level in the market.
Future Health: Datwyler’s goal is set to constantly strive to deliver excellence, set new industry standards and shape the development of its markets. By leveraging superior knowledge and innovative technologies, Datwyler is prepared for tomorrow’s needs and expectations, thereby helping its customers to stay ahead in the age of digital transformation. The company’s future-oriented innovations aim to improve personal health by advancing new solutions, leveraging new therapies and providing state-of-the-art components for wearable health care devices.
Global Leadership: As a leading supplier, Datwyler continues to build its global capabilities and presence in key markets around the world. By entering emerging markets, leveraging lean production processes and building upon an optimized supply chain, the company is prepared to master the challenges of the global health care industry while ensuring efficient market access, maintaining a competitive edge and remaining a reliable partner around the globe.
New offering categories for more transparency
In order to better meet customer needs and expectations and to provide more transparency for its high quality solutions, Datwyler developed three different offering categories:
- Bio Care offers solutions for the most sensitive, large molecule drugs. Components of this category also provide the lowest available particle levels in the industry.
- Pharma Care addresses the needs of small molecule drugs which require production flexibility and outstanding quality.
- Med Care offers medical companies a broad range of materials and technical support.
Strengthening Datwyler’s position in the U.S. pharmaceutical market
In addition to the introduction of the new health care offering, Datwyler gave insights into the company’s overall strategy and expansion plans for strengthening its position in the U.S., the world’s largest pharmaceutical market. The company is channelling more than $100 million into building a new plant in Delaware, which will run in accordance with Datwyler’s most advanced standard: First Line. The First Line production standard is specially designed to manufacture pharmaceutical elastomer components in a fully integrated good manufacturing practice (GMP) environment conforming to the highest industry standards.
The new facility will be used to manufacture high-quality elastomer components for injectable drug delivery systems. Production is scheduled to start in 2018. Once it is fully up and running, the highly automated plant will provide jobs for around 120 employees. This investment will enable Datwyler to better provide customers in its three key business regions, the U.S., Europe and Asia, with locally produced components of the highest quality – now, and in the future.
First Line standard for high-quality elastomer components
The First Line standard is the result of a manufacturing concept for high-quality elastomer components and is based on ultra-modern cleanroom technology, automated production cells, fully automated camera inspection and a unique validated washing process. This innovative approach to manufacturing exceeds the most stringent quality standards of the European and US regulatory authorities and is certified to ISO 15378.
For more information on Datwyler’s new health care offering and a chance to speak to one of Datwyler’s representatives, please visit the company’s booth no. 1546 from March 21-23 at INTERPHEX 2017.